A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).

Authors: Ghatalia, Pooja, Ross, Eric A., Zibelman, Matthew R., Anari, Fern, Abbosh, Philip, Tester, William J, Rose, Tracy L., Cole, Suzanne, Mark, James Ryan, Viterbo, Rosalia, Jerome, Erika, Horwitz, Eric M., Hallman, Mark A, Correa, Andres F, Smaldone, Marc C., Uzzo, Robert, Chen, David YT, Kutikov, Alexander, Plimack, Elizabeth R., Geynisman, Daniel M.

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p815-815, 242p

Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC): A meta-analysis.

Authors: Saxena, Abhiraj, Zorko, Nicholas, Narayan, Vivek, Saraiya, Biren, Tester, William J, Lu-Yao, Grace L., Kelly, William Kevin, Zarrabi, Kevin Kayvan

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p128-128, 288p

Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial

Authors: Steuer, Conor E., Jegede, Opeyemi A., Dahlberg, Suzanne E., Wakelee, Heather A., Keller, Steven M., Tester, William J., Gandara, David R., Graziano, Stephen L., Adjei, Alex A., Butts, Charles A., Ramalingam, Suresh S., Schiller, Joan H.

Source: In Journal of Thoracic Oncology June 2021 16(6):960-967

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

Authors: Wakelee, Heather A, Dahlberg, Suzanne E, Keller, Steven M, Tester, William J, Gandara, David R, Graziano, Stephen L, Adjei, Alex A, Leighl, Natasha B, Aisner, Seena C, Rothman, Jan M, Patel, Jyoti D, Sborov, Mark D, McDermott, Sean R, Perez-Soler, Roman, Traynor, Anne M, Butts, Charles, Evans, Tracey, Shafqat, Atif, Chapman, Andrew E, Kasbari, Samer S, Horn, Leora, Ramalingam, Suresh S, Schiller, Joan H

Source: In The Lancet Oncology December 2017 18(12):1610-1623

Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.

Authors: Eturi, Aditya, Bhasin, Amman, Zarrabi, Kevin K., Tester, William J.

Source: Molecules; Apr2024, Vol. 29 Issue 8, p1896, 18p

Subject Terms: TUMOR antigens, PROGNOSIS, TUMOR markers, POLY ADP ribose, EPIDERMAL growth factor receptors, TRANSITIONAL cell carcinoma, ADP-ribosylation, FIBROBLAST growth factor receptors

T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.

Authors: Palecki, Julia, Bhasin, Amman, Bernstein, Andrew, Mille, Patrick J., Tester, William J., Kelly, Wm. Kevin, Zarrabi, Kevin K.

Source: Cancer Biology & Therapy; 2024, Vol. 25 Issue 1, p1-12, 12p

Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer

Authors: Zhang, Zhenchao, Luo, Rui, Kelly, William K., Chen, Joshua, Donahue, Shane, Ip, Kevan, Handley, Nathan R., Tester, William J., Tsang, Miranda L., Kim, Felix J., Myers, Ronald, Lu-Yao, Grace, Gu, Jian, Lin, Jianqing, Li, Bingshan, Wang, Chun, Yang, Hushan

Source: Prostate Cancer and Prostatic Diseases; 20230101, Issue: Preprints p1-9, 9p

A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group study (PZ586)

Authors: Tester, William J. ^*, Kim, Kyung Mann, Krigel, Robert L., Bonomi, Philip D., Glick, John H., Asbury, Robert F., Kirkwood, John M., Blum, Ronald H., Schiller, Joan H.

Source: In Lung Cancer 1999 25(3):199-206

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy.

Authors: Magliocco, Anthony M., Moughan, Jennifer, Miyamoto, David T., Simko, Jeff, Shipley, William U., Gray, Phillip J., Hagan, Michael P., Parliament, Matthew, Tester, William J., Zietman, Anthony L., McCarthy, Susan, Saeed-Vafa, Daryoush, Xiong, Yin, Ayral, Taylor, Hartford, Alan C., Patel, Ashish, Rosenthal, Seth A., Chafe, Susan, Greenberg, Richard, Schwartz, Michael A.

Source: JAMA Network Open; 11/16/2022, Vol. 5 Issue 11, pe2242378-e2242378, 1p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion.

Authors: Tester, William J., Jin, Pamela Y., Reardon, Deborah H., Cohn, Jeffrey B., Cohen, Martin H.

Source: Cancer (0008543X); Feb1997, Vol. 79 Issue 4, p724-729, 6p

Overview of bladder cancer trials in the Radiation Therapy Oncology GroupBased on a Satellite Symposium held in conjunction with the First European Conference on Perspectives in Bladder Cancer, Monte Carlo, Monaco, November 16–17, 2001.

Authors: Shipley, William U., Kaufman, Donald S., Tester, William J., Pilepich, Miljenko V., Sandler, Howard M.

Source: Cancer; 15 April 2003, Vol. 97 Issue: Supplement 8 p2115-2119, 5p

Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors

Authors: Tester, William J., Donehower, Ross C., Eddy, Joyce L., Myers, Charles E., Ihde, Daniel C.

Source: Cancer Chemotherapy and Pharmacology; August 1982, Vol. 8 Issue: 3 p305-310, 6p

This result is not displayed to guests.
Login for full access.